Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Rating of “Hold” from Brokerages

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have been given a consensus recommendation of “Hold” by the eight brokerages that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $3.9417.

Several analysts have recently weighed in on DH shares. Barclays decreased their price target on shares of Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a research note on Monday, December 8th. William Blair upgraded Definitive Healthcare to a “strong-buy” rating in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definitive Healthcare in a research report on Wednesday, January 21st. Canaccord Genuity Group decreased their price objective on Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating for the company in a report on Monday, November 10th. Finally, Morgan Stanley reiterated an “underperform” rating and set a $3.50 target price on shares of Definitive Healthcare in a report on Thursday, December 18th.

Hedge Funds Weigh In On Definitive Healthcare

A number of large investors have recently bought and sold shares of DH. State of Alaska Department of Revenue boosted its position in Definitive Healthcare by 109.3% during the 4th quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock valued at $32,000 after acquiring an additional 5,970 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Definitive Healthcare during the 2nd quarter worth $32,000. Farther Finance Advisors LLC purchased a new stake in shares of Definitive Healthcare during the 2nd quarter worth $33,000. Savant Capital LLC bought a new stake in Definitive Healthcare during the second quarter valued at about $45,000. Finally, SG Americas Securities LLC purchased a new position in Definitive Healthcare in the fourth quarter valued at about $46,000. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Stock Up 1.8%

Shares of DH opened at $2.32 on Monday. The firm has a fifty day moving average price of $2.52 and a 200-day moving average price of $3.18. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $327.96 million, a P/E ratio of -1.39 and a beta of 1.59. Definitive Healthcare has a 12-month low of $2.15 and a 12-month high of $5.68.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The company had revenue of $60.05 million during the quarter, compared to analyst estimates of $59.51 million. Definitive Healthcare had a negative net margin of 77.88% and a positive return on equity of 3.30%. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS and its Q4 2025 guidance at 0.050-0.060 EPS. Equities research analysts expect that Definitive Healthcare will post 0.16 earnings per share for the current year.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.